Govt panel recommends market authorisation for Covovax jab as heterologous booster dose

 

 

AN EXPERT panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s COVID vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Thursday.

Prakash Kumar Singh, director (Government and Regulatory Affairs) at Serum Institute of India (SII) had recently written a letter to Drugs Controller General of India (DCGI) for approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating COVID-19 pandemic situation in some countries, the sources said.

“The subject expert committee (SEC) of the CDSCO on Wednesday deliberated on the issue and recommended for market authorisation of COVID jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin,” an official source said.